PortalPublikationenProgression free survival of first line vascular endothelial...

Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.

Standard

Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. / Seidel, Christoph; Busch, Jonas; Weikert, Steffen; Steffens, Sandra; Fenner, Martin; Ganser, Arnold; Grünwald, Viktor.

in: EUR J CANCER, Jahrgang 48, Nr. 7, 7, 2012, S. 1023-1030.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Seidel, C, Busch, J, Weikert, S, Steffens, S, Fenner, M, Ganser, A & Grünwald, V 2012, 'Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.', EUR J CANCER, Jg. 48, Nr. 7, 7, S. 1023-1030. <http://www.ncbi.nlm.nih.gov/pubmed/22436979?dopt=Citation>

APA

Seidel, C., Busch, J., Weikert, S., Steffens, S., Fenner, M., Ganser, A., & Grünwald, V. (2012). Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. EUR J CANCER, 48(7), 1023-1030. [7]. http://www.ncbi.nlm.nih.gov/pubmed/22436979?dopt=Citation

Vancouver

Seidel C, Busch J, Weikert S, Steffens S, Fenner M, Ganser A et al. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. EUR J CANCER. 2012;48(7):1023-1030. 7.

Bibtex

@article{b32ec9de86944b298aed2508c129df11,
title = "Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.",
abstract = "Intrinsic resistance in metastatic renal cell carcinoma (mRCC) was recently associated with poor overall survival (OS), suggesting that VEGF inhibitor sensitivity may represent a valuable prognostic marker. We explored the duration of progression free survival (PFS) in first-line treatment and other variables as prognostic markers in mRCC.",
keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Treatment Outcome, Prognosis, Disease-Free Survival, Molecular Targeted Therapy, Kidney Neoplasms/*drug therapy/pathology, Vascular Endothelial Growth Factor A/*antagonists & inhibitors, Protein Kinase Inhibitors/administration & dosage, Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use, Carcinoma, Renal Cell/*drug therapy/pathology/secondary, Adult, Humans, Male, Aged, Female, Middle Aged, Treatment Outcome, Prognosis, Disease-Free Survival, Molecular Targeted Therapy, Kidney Neoplasms/*drug therapy/pathology, Vascular Endothelial Growth Factor A/*antagonists & inhibitors, Protein Kinase Inhibitors/administration & dosage, Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use, Carcinoma, Renal Cell/*drug therapy/pathology/secondary",
author = "Christoph Seidel and Jonas Busch and Steffen Weikert and Sandra Steffens and Martin Fenner and Arnold Ganser and Viktor Gr{\"u}nwald",
year = "2012",
language = "English",
volume = "48",
pages = "1023--1030",
journal = "EUR J CANCER",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "7",

}

RIS

TY - JOUR

T1 - Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.

AU - Seidel, Christoph

AU - Busch, Jonas

AU - Weikert, Steffen

AU - Steffens, Sandra

AU - Fenner, Martin

AU - Ganser, Arnold

AU - Grünwald, Viktor

PY - 2012

Y1 - 2012

N2 - Intrinsic resistance in metastatic renal cell carcinoma (mRCC) was recently associated with poor overall survival (OS), suggesting that VEGF inhibitor sensitivity may represent a valuable prognostic marker. We explored the duration of progression free survival (PFS) in first-line treatment and other variables as prognostic markers in mRCC.

AB - Intrinsic resistance in metastatic renal cell carcinoma (mRCC) was recently associated with poor overall survival (OS), suggesting that VEGF inhibitor sensitivity may represent a valuable prognostic marker. We explored the duration of progression free survival (PFS) in first-line treatment and other variables as prognostic markers in mRCC.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Treatment Outcome

KW - Prognosis

KW - Disease-Free Survival

KW - Molecular Targeted Therapy

KW - Kidney Neoplasms/drug therapy/pathology

KW - Vascular Endothelial Growth Factor A/antagonists & inhibitors

KW - Protein Kinase Inhibitors/administration & dosage

KW - Antineoplastic Agents/administration & dosage/adverse effects/therapeutic use

KW - Carcinoma, Renal Cell/drug therapy/pathology/secondary

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Treatment Outcome

KW - Prognosis

KW - Disease-Free Survival

KW - Molecular Targeted Therapy

KW - Kidney Neoplasms/drug therapy/pathology

KW - Vascular Endothelial Growth Factor A/antagonists & inhibitors

KW - Protein Kinase Inhibitors/administration & dosage

KW - Antineoplastic Agents/administration & dosage/adverse effects/therapeutic use

KW - Carcinoma, Renal Cell/drug therapy/pathology/secondary

M3 - SCORING: Journal article

VL - 48

SP - 1023

EP - 1030

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

IS - 7

M1 - 7

ER -